Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats
10.1016/j.afos.2018.08.003
- Author:
Boohwi HONG
1
;
Sunyeul LEE
;
Nara SHIN
;
Youngkwon KO
;
DongWoon KIM
;
Jun LEE
;
Wonhyung LEE
Author Information
1. Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, South Korea. whlee@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Mesenchymal stem cell transplantation;
Osteoporosis
- MeSH:
Animals;
Bone Development;
Bone Regeneration;
Female;
Fetal Blood;
Humans;
Mesenchymal Stem Cell Transplantation;
Mesenchymal Stromal Cells;
Models, Animal;
Osteoblasts;
Osteogenesis;
Osteoporosis;
Ovariectomy;
Rats;
Stem Cells;
Umbilical Cord
- From:Osteoporosis and Sarcopenia
2018;4(3):99-105
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: Current treatments for osteoporosis were prevention of progression, yet it has been questionable in the stimulation of bone growth. The mesenchymal stem cells (MSCs) treatment for osteoporosis aims to induce differentiation of bone progenitor cells into bone-forming osteoblasts. We investigate whether human umbilical cord blood (hUCB)-MSCs transplantation may induce bone regeneration for osteoporotic rat model induced by ovariectomy. METHODS: The ovariectomized (OVX) group (n = 10) and OVX-MSCs group (n = 10) underwent bilateral ovariectomy to induce osteoporosis, while the Sham group (n = 10) underwent sham operation at aged 12 weeks. After a femoral defect was made at 9 months, Sham group and OVX group were injected with Hartmann solution, while the OVX-MSCs group was injected with Hartmann solution containing 1 × 107 hUCB-MSCs. The volume of regenerated bone was evaluated using micro-computed tomography at 4 and 8 weeks postoperation. RESULTS: At 4- and 8-week postoperation, the OVX group (5.0% ± 1.5%; 6.1% ± 0.7%) had a significantly lower regenerated bone volume than the Sham group (8.6% ± 1.3%; 12.0% ± 1.8%, P < 0.01), respectively. However, there was no significant difference between the OVX-MSCs and Sham groups. The OVX-MSCs group resulted in about 53% and 65% significantly higher new bone formation than the OVX group (7.7% ± 1.9%; 10.0% ± 2.9%, P < 0.05). CONCLUSIONS: hUCB-MSCs in bone defects may enhance bone regeneration in osteoporotic rat model similar to nonosteoporotic bone regeneration. hUCB-MSCs may be a promising alternative stem cell therapy for osteoporosis.
